Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore changes in efficacy, cognitive functioning, and
safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.